Logo-ipp
Submitted: 06 Dec 2021
Accepted: 10 Feb 2022
ePublished: 20 Feb 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Immunopathol Persa. 2022;8(2): e31373.
doi: 10.34172/ipp.2022.31373
  Abstract View: 411
  PDF Download: 447

Case Report

Benralizumab substitution monotherapy in symptomatic relapsing asthma-dominant eosinophilic granulomatosis with polyangiitis

Macaulay Amechi Chukwukadibia Onuigbo 1* ORCID logo, Bonita Libman 2, Mark Lazarovich 3

1 Division of Nephrology, Department of Medicine, The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, USA
2 Division of Rheumatology, Department of Medicine, The Robert Larner, M.D. College of Medicine, University of Vermont, Burlington, VT, USA
3 Timber Lane Allergy and Asthma Associates, 53 Timber Lane, S Burlington, VT 05403, USA
*Corresponding Author: *Correspondence to Macaulay Amechi Chukwukadibia Onuigbo, Email: , Email: macaulay.onuigbo@ uvmhealth.org

Abstract

There is increasing interest in biologicals in steroid-resistant or steroid-dependent eosinophilic granulomatosis with polyangiitis (EGPA). We describe successful benralizumab monotherapy in asthma-dominant EGPA. Sixteen years ago, a 38-year-old male was diagnosed with multisystemic illness with asthma, arthralgias, Bell’s palsy and nephrotic syndrome, with 20.3% eosinophilia (absolute count 1160 K/µL), ESR 50 mm/hour, albumin 2.3 g/dL, serum creatinine 1.1 mg/dL, slightly above baseline and negative immunology work. Kidney biopsy demonstrated diffuse podocyte foot process effacement with minimal change disease, without vasculitis and EGPA was diagnosed. He achieved early remission with corticosteroids and intravenous cyclophosphamide and was maintained on prednisone and mycophenolate mofetil. Nevertheless, he repeatedly experienced severe asthma exacerbations, falls in FEV-1% and recurrent relapsing eosinophilia. He was successfully started on benralizumab and was weaned off mycophenolate mofetil and prednisone. Eosinophilia was corrected and FEV-1% normalized. We support calls for larger trials of the biologicals in EGPA.

Citation: Onuigbo MAC, Libman B, Lazarovich M. Benralizumab substitution monotherapy in symptomatic relapsing asthmadominant eosinophilic granulomatosis with polyangiitis. Immunopathol Persa. 2022;8(2):e31373. DOI:10.34172/ ipp.2022.31373.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 412

Your browser does not support the canvas element.


PDF Download: 447

Your browser does not support the canvas element.